LinkMed's new share issue heavily oversubscribed

Press release
June 10, 2009	


LinkMed's new share issue heavily oversubscribed 

Calculation of the outcome of the new share issue implemented by LinkMed shows
that the issue was oversubscribed by 41 percent, which means that the guarantee
commitments entered into need not be utilized. As a result of the new share
issue, LinkMed will receive approximately SEK 91.3 million, before issue
expenses.

Of the new share issue, 98.5 percent, corresponding to 7,192,444 shares, were
subscribed for on the basis of subscription rights. Applications to subscribe
for shares without the support of subscription rights were made for
approximately 42.7 percent of the issue, equivalent to 3,118,527 shares. New
shares subscribed for without the support of subscription rights were allotted
to shareholders who had subscribed for shares on the basis of subscription
rights, in accordance with the principles stated in the prospectus published on
May 12, 2009. A statement will be sent on or around June 10, 2009 confirming
allotment of new shares to those subscribers who subscribed for new shares
without the support of subscription rights. 

“Naturally, we are very pleased that such great interest was shown in LinkMed.
The new share issue will give us the opportunity to create a well-positioned and
profitable transplantation sector company by combining AbSorber and Olerup, in
which the first steps may be a joint sales organization and the coordination of
the resources of the two companies. We also now have the opportunity to continue
to support the development of BioResonator, Biovator, Likvor and Ortoviva, all
of which are at very interesting stages, with products close to market launch,”
said Ingemar Lagerlöf, CEO LinkMed.

As a result of the new share issue, the number of LinkMed shares will increase
by 7,300,873 to 16,061,921 shares. Share capital will increase by SEK 7,300,873
to SEK 16,061,921.

Paid subscription shares (”BTAs”) will be traded on NASDAQ OMX Stockholm until
partial registration of the new shares with the Swedish Companies Registration
Office has been effected. Only first class BTAs will be traded on NASDAQ OMX
Stockholm. New shares subscribed to on the basis of subscription rights are
expected to become subject to trading on NASDAQ OMX Stockholm on June 17, 2009.
Shares subscribed to without preferential rights are expected to become subject
to trading at the beginning of July 2009.

Changes among the company's principal shareholders have occurred in conjunction
with the new share issue. An updated list of the 15 largest shareholders will be
published on LinkMed's website upon completion of the issue. 

Financial and legal advisors
Swedbank Markets is LinkMed's financial advisor and Advokatfirman Lindahl is the
company's legal advisor.


For more information please contact:
Ingemar Lagerlöf, CEO: +46 8 508 939 93
Okee Williams, Portfolio Manager +46 8 508 939 40

Visit LinkMed's website: www.linkmed.se

IMPORTANT INFORMATION

The information in this press release is not intended for distribution,
publication or disclosure, directly or indirectly, in or into the United States,
Canada, Australia, Hong Kong, Japan or New Zealand.
The information in this press release shall not be regarded as an offer to sell
shares or a request to acquire shares. Nor will any sale of the securities
referred to herein be permissible in any jurisdiction where such an offer,
request or sale would not be lawful without registration or applicable exemption
from registration pursuant to the securities legislation of such a jurisdiction.
A prospectus concerning the rights issue presented in this press release and the
subsequent listing of new shares on NASDAQ OMX Stockholm has been prepared and
has been approved and registered by the Swedish Financial Supervisory Authority.

The information in this press release does not constitute an offering of LinkMed
securities in the U.S.; nor will the securities be offered or sold in the
absence of registration or exemption from registration pursuant to the American
Securities Act of 1933, as well as the rules and regulations under this act.
There is no intention of registering any part of an offering of LinkMed
securities in the US or of implementing a public offering of shares in the US.

The information in this press release may not be forwarded or distributed to any
third party; nor may it be reproduced in any manner. It is not permissible to
forward, distribute, reproduce or disclose this information, in full or in part.
Failure to observe these directives could constitute a breach of the American
Securities Act of 1933 or applicable laws in other jurisdictions.


LinkMed develops life science companies in collaboration with innovators and
other financiers. By contributing management expertise and capital, LinkMed has
created a portfolio of twelve companies, four in drug development and
biotechnology and eight in diagnostics and medical technology. The company's
principal shareholders are among others FastPartner, Koncentra Holding and the
founder Ingemar Lagerlöf. LinkMed is listed on the NASDAQ OMX Nordic Exchange in
the Small Cap section (ticker: LMED).